90 results on '"Hirsch, Alan T."'
Search Results
2. Nutritional status and body composition in patients with peripheral arterial disease: A cross-sectional examination of disease severity and quality of life.
- Author
-
Brostow, Diana P., Hirsch, Alan T., Pereira, Mark A., Bliss, Robin L., and Kurzer, Mindy S.
- Subjects
- *
ARTERIAL diseases , *NUTRITIONAL status , *BODY composition , *QUALITY of life , *CROSS-sectional method , *LEG pain , *PATIENTS - Abstract
Nutritional and body weight recommendations for cardiovascular diseases are well established, yet there are no equivalent guidelines for peripheral arterial disease (PAD). This cross-sectional study measured the prevalence of cardiovascular-related nutritional and body composition risk factors in sixty PAD patients and their association with PAD severity. A diet that exceeds daily recommended intake of fat and that falls short of recommended intakes of fiber, folate, and vitamin D was associated with increased leg pain and walking difficulty. Increased body fat and waist circumference were associated with diminished walking ability and poorer psychosocial quality of life. Future prospective investigations are merited to inform both PAD clinical care and disease management guidelines. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Recruiting older patients with peripheral arterial disease: evaluating challenges and strategies.
- Author
-
Brostow, Diana P., Hirsch, Alan T., and Kurzer, Mindy S.
- Subjects
- *
ARTERIAL diseases , *DISEASES in older people , *ATHEROSCLEROSIS , *CARDIOVASCULAR diseases , *MORTALITY of older people , *PATIENTS - Abstract
Peripheral arterial disease (PAD) is a group of syndromes characterized by chronic and progressive atherosclerosis with a high burden of physical disability and cardiovascular morbidity and mortality. Recruiting patients for clinical research is therefore challenging. In this article, we describe and evaluate our methods for recruiting participants for a cross-sectional feasibility study of PAD, nutritional status, and body composition. We used convenience and purposive sampling approaches to identify potential participants. Between May 2012 and April 2013, 1,446 patients were identified, and 165 patients (11.4%) responded to recruitment requests. The final enrollment was 64 participants (64/1,446; 4.4%), and four subjects (6.3%) subsequently withdrew from the study. Recruiting PAD patients presents a variety of challenges, due largely to the burdens of living with coexistent illnesses, and patients' reluctance or inability to travel for research. In this article, we delineate suggestions for improving the efficacy of recruitment methods in future PAD studies. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
4. Lymphedema Prevalence and Treatment Benefits in Cancer: Impact of a Therapeutic Intervention on Health Outcomes and Costs.
- Author
-
Brayton, Kimberly M., Hirsch, Alan T., O′Brien, Patricia J., Cheville, Andrea, Karaca-Mandic, Pinar, and Rockson, Stanley G.
- Subjects
- *
LYMPHEDEMA treatment , *DISEASE prevalence , *CANCER treatment , *TREATMENT effectiveness , *CANCER complications , *CANCER patients - Abstract
Background: Lymphedema is a common complication of cancer therapeutics; its prevalence, treatment outcomes, and costs have been poorly defined. The objective of this study was to examine lymphedema prevalence among cancer survivors and to characterize changes in clinical outcomes and costs associated with a defined therapeutic intervention (use of a pneumatic compression devices [PCD]) in a representative, privately insured population. Methods and Findings: Retrospective analysis of de-identified health claims data from a large national insurer for calendar years 2007 through 2013. Patients were required to have 12 months of continuous insurance coverage prior to PCD receipt (baseline), as well as a 12-month follow-up period. Analyses were performed for individuals with cancer-related lymphedema (n = 1,065). Lymphedema prevalence was calculated: number of patients with a lymphedema claim in a calendar year divided by total number of enrollees. The impact of PCD use was evaluated by comparing rates of a pre-specified set of health outcomes and costs for the 12 months before and after, respectively, PCD receipt. Lymphedema prevalence among cancer survivors increased from 0.95% in 2007 to 1.24% in 2013. PCD use was associated with decreases in rates of hospitalizations (45% to 32%, p<0.0001), outpatient hospital visits (95% to 90%, p<0.0001), cellulitis diagnoses (28% to 22%, p = 0.003), and physical therapy use (50% to 41%, p<0.0001). The average baseline health care costs were high ($53,422) but decreased in the year after PCD acquisition (−$11,833, p<0.0001). Conclusions: Lymphedema is a prevalent medical condition that is often a defining attribute of cancer survivorship. The problem is associated with high health care costs; Treatment (in this instance, use of PCD) is associated with significant decreases in adverse clinical outcomes and costs. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
5. The role of nutrition and body composition in peripheral arterial disease.
- Author
-
Brostow, Diana P., Hirsch, Alan T., Collins, Trade C., and Kurzer, Mindy S.
- Subjects
- *
NUTRITION , *HUMAN body composition , *ARTERIAL diseases , *CARDIOVASCULAR diseases , *LOW density lipoproteins - Abstract
Peripheral arterial disease (PAD) has not been as extensively investigated as other cardiovascular diseases. However, the available data suggest that nutrition-based treatment strategies have the potential to reduce the cost- economic burden of PAD substantially. Abdominal obesity is associated with PAD and prospective and cross-sectional studies have shown that a low dietary intake of folate and reduced synthesis of vitamin D are associated with an increased risk of PAD and severe walking impairment in patients who have the disease. However, dietary patterns that are associated with decreased cardiovascular risk might protect against PAD. A small number of clinical trials have provided evidence that increased intakes of niacin and insoluble fiber might be associated with decreased levels of LDL cholesterol and thrombogenic biomarkers, as well as increased serum levels of HDL cholesterol in patients with PAD. However, little evidence that antioxidants, vitamins B6 and B12 or essential fatty acid supplements improve clinical outcomes in these patients exists. Overall, data on the effects of nutrition, body composition, and nutritional supplementation on the risk, progression, and prognosis of PAD are scarce. Further research into these areas is required to allow the development of evidence-based nutritional guidelines for the prevention and treatment of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
6. A Call to Action: Women and Peripheral Artery Disease: A Scientific Statement From the American Heart Association.
- Author
-
Hirsch, Alan T., Allison, Matthew A., Gomes, Antoinette S., Corriere, Matthew A., Duval, Sue, Ershow, Abby G., Hiatt, William R., Karas, Richard H., Lovell, Marge B., McDermott, Mary M., Mendes, Donna M., Nussmeier, Nancy A., and Treat-Jacobson, Diane
- Subjects
- *
CARDIOVASCULAR disease treatment , *DISEASES in women , *DISEASE prevalence , *RESEARCH & development - Abstract
The article discusses the impact, epidemiology and treatment of peripheral artery disease (PAD) for women in the U.S. It is discussed that the American Heart Association and Vascular Disease Foundation have commissioned a statement to describe cardiovascular risks and evidences regarding the burden of PAD in women. It further informs that the evidences for the epidemiology of disease in women are incomplete and there is insufficiency of research on PAD women.
- Published
- 2012
- Full Text
- View/download PDF
7. Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease.
- Author
-
Hiatt, William R., Hirsch, Alan T., Creager, Mark A., Rajagopalan, Sanjay, Mohler, Emile R., Ballantyne, Christie M., Regensteiner, Judith G., Treat-Jacobson, Diane, and Dale, Rita A.
- Subjects
- *
NIACIN , *VASCULAR diseases , *ATHEROSCLEROSIS , *CHOLESTEROL , *HIGH density lipoproteins , *LOW density lipoproteins , *DRUG therapy , *HYPERLIPIDEMIA - Abstract
In patients with peripheral artery disease (PAD), statins may improve the symptoms of claudication. The Intermittent Claudication Proof of Principle (ICPOP) study tested the hypothesis that the combination of extended release niacin plus lovastatin would improve exercise performance in patients with PAD and claudication compared with a diet intervention. A phase 3 double-blind, parallel-group, multi-center, 28-week multi-national study evaluated subjects with a history of claudication who had an ankle-brachial index (ABI) ≤ 0.90, a reproducible peak treadmill walking time (PWT) of 1-20 minutes, and a low-density lipoprotein (LDL)-cholesterol level < 160 mg/dl (< 4.1 mmol/l). Subjects were randomly assigned to low-dose niacin 1000 mg plus lovastatin 40 mg (low niacin-statin), high-dose niacin 2000 mg plus lovastatin 40 mg (high niacin-statin), or diet intervention (diet). The co-primary efficacy endpoint of percent change in PWT and claudication onset time (COT) at 28 weeks was assessed using a graded treadmill protocol. At completion, 385 subjects were analyzed for safety and 370 subjects were analyzed for efficacy. The primary efficacy analysis showed no statistical significance for overall treatment effect at week 28 for the co-primary endpoint of PWT and COT. The PWT component of the primary endpoint increased 26.5% on diet, 37.8% on high niacin-statin (p = 0.137) and 38.6% on low niacin-statin (p = 0.096). Flushing as the most common event leading to discontinuation and treatment was associated with increases in liver enzymes, fasting blood glucose concentration and a decrease in platelet count. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
8. The efficacy and safety of enhanced external counterpulsation in patients with peripheral arterial disease.
- Author
-
Thakkar, Bhavik V., Hirsch, Alan T., Satran, Daniel, Bart, Bradley A., Barsness, Gregory, McCullough, Peter A., Kennard, Elizabeth D., Kelsey, Sheryl F., and Henry, Timothy D.
- Subjects
- *
ENHANCED external counterpulsation , *ARTERIAL diseases , *CORONARY disease , *CARDIOVASCULAR diseases , *MYOCARDIAL infarction , *ANGINA pectoris - Abstract
Peripheral arterial disease (PAD) is common in patients with severe coronary artery disease (CAD) and is considered a relative contraindication to external enhanced counterpulsation (EECP), but there are no data that define the efficacy and safety of EECP in patients with PAD. The International EECP Patient Registry (IEPR) was used to compare initial posttherapy and 2-year follow-up clinical outcomes and adverse event rates in patients with and without PAD. From January 2002 to October 2004, 2126 patients were enrolled in the IEPR, of whom 493 (23%) had a history of PAD. Immediately following EECP, the reduction in angina (≥ 1 Canadian Cardiovascular Society class) was similar in patients with and without PAD (76.6% vs 79.0%, p = 0.27) as was improvement in the Duke Activity Score Index (DASI) score (+4.7% vs +6.1%, p < 0.001). Both angina reduction and DASI score improvement were sustained at 2 years. PAD patients discontinued EECP more frequently (12.0% vs 8.5%, p < 0.05), but lower extremity ulceration did not occur more frequently in patients with PAD (3.7% vs 2.7%, p = 0.26). Rates of death (17.1% vs 8.6%, p < 0.001) and myocardial infarction (9.5% vs 5.0%, p < 0.001) were, as expected, higher in patients with PAD compared to patients without PAD at 2 years. In conclusion, while PAD patients constitute a high-risk cohort with known higher adverse event rates, EECP led to similar short- and longterm improvements in angina and quality of life for individuals with PAD compared to those without PAD. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
9. Design of the multicenter standardized supervised exercise training intervention for the 'CLaudication: Exercise Vs Endoluminal Revascularization (CLEVER) study'.
- Author
-
Bronas, Ulf G., Hirsch, Alan T., Murphy, Timothy, Badenhop, Dalynn, Collins, Tracie C., Ehrman, Jonathan K., Ershow, Abby G., Lewis, Beth, Treat-Jacobson, Diane J., Walsh, M. Eileen, Oldenburg, Niki, and Regensteiner, Judith G.
- Subjects
- *
MEDICAL research , *MEDICAL rehabilitation , *PHYSICAL fitness , *EXERCISE therapy , *MEDICAL care - Abstract
The CLaudication: Exercise Vs Endoluminal Revascularization (CLEVER) study is the first randomized, controlled, clinical, multicenter trial that is evaluating a supervised exercise program compared with revascularization procedures to treat claudication. In this report, the methods and dissemination techniques of the supervised exercise training intervention are described. A total of 217 participants are being recruited and randomized to one of three arms: (1) optimal medical care; (2) aortoiliac revascularization with stent; or (3) supervised exercise training. Of the enrolled patients, 84 will receive supervised exercise therapy. Supervised exercise will be administered according to a protocol designed by a central CLEVER exercise training committee based on validated methods previously used in single center randomized control trials. The protocol will be implemented at each site by an exercise committee member using training methods developed and standardized by the exercise training committee. The exercise training committee reviews progress and compliance with the protocol of each participant weekly. In conclusion, a multicenter approach to disseminate the supervised exercise training technique and to evaluate its efficacy, safety and cost-effectiveness for patients with claudication due to peripheral arterial disease (PAD) is being evaluated for the first time in CLEVER. The CLEVER study will further establish the role of supervised exercise training in the treatment of claudication resulting from PAD and provide standardized methods for use of supervised exercise training in future PAD clinical trials as well as in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
10. Contemporary risk factor control and walking dysfunction in individuals with peripheral arterial disease: NHANES 1999–2004
- Author
-
Selvin, Elizabeth and Hirsch, Alan T.
- Subjects
- *
CORONARY heart disease risk factors , *HEART diseases , *THERAPEUTICS , *PERIPHERAL vascular diseases , *EPIDEMIOLOGY , *HEALTH surveys , *HYPERTENSION , *PATIENTS - Abstract
Abstract: Background: Lower extremity peripheral arterial disease (PAD) is a coronary heart disease (CHD) risk equivalent. Selected studies have demonstrated less intense risk factor management and diminished mobility in individuals with PAD as compared to individuals with clinical recognized CHD. However, comparable data have not been reported from a nationally representative population. Objectives: To assess the prevalence, treatment, and control of cardiovascular risk factors among individuals with PAD as defined by an ankle-brachial index (ABI) <0.90 (but without recognized CHD) as compared with individuals with recognized CHD (but without PAD). A second objective was to evaluate the diagnostic accuracy of measures of walking dysfunction to identify individuals with PAD. Design, setting, and participants: We analyzed data from 7571 participants aged 40 or older who participated in the National Health and Nutrition Examination Survey (NHANES) 1999–2004, a nationally representative cross-sectional survey of the U.S. population. Results: The prevalence of PAD without CHD was 4.1% (95% CI 3.6–4.5) compared to 7.9% (7.1, 8.9) for CHD (without PAD). Hypertension prevalence was similar, but treatment and control rates were lower among individuals with PAD compared to CHD (treatment: 69% vs. 84%, p <0.001; control: 50% vs. 63%, p =0.01). Treatment of hypercholesterolemia was lower among individuals with PAD (54% vs. 79%, p <0.001) but control was similar (83% vs. 85%, p =0.78). Diabetes awareness, treatment, and control did not differ between the two groups. Walking mobility limitations were specific, but insensitive, for the identification of individuals with PAD. Conclusion: PAD in the absence of clinically recognized CHD is under-treated and poorly controlled in the general U.S. population. Leg symptoms are not adequate to identify individuals with PAD, who are at high risk of ischemic events. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
11. National health care costs of peripheral arterial disease in the Medicare population.
- Author
-
Hirsch, Alan T., Hartman, Lacey, Town, Robert J., and Virnig, Beth A.
- Subjects
- *
PUBLIC health , *HEALTH insurance , *CEREBROVASCULAR disease risk factors , *CORONARY disease ,MYOCARDIAL infarction-related mortality - Abstract
Lower extremity peripheral arterial disease (PAD) is prevalent in the Medicare population and is associated with high rates of myocardial infarction, stroke, amputation, and death. Nevertheless, national health expenditures for PAD are not known. We hypothesized that PAD-related costs are high, increase with age, and that treatment rates would be less than known PAD prevalence. The objective was to determine national health care expenditures for PAD in the United States. PAD-related treatment costs were calculated in the elderly, non-disabled Medicare population. The cost analysis relied on the 5% control population for the linked SEER- Medicare data and Medicare claims for the calendar year 2001, identifying PAD cases based on diagnosis and procedure codes. Costs were aggregated separately for inpatient and outpatient treatment and estimates adjusted to reflect the Medicare population. A total of $4.37 billion was spent on PAD-related treatment and 88% of expenditures were for inpatient care. Medicare program outlays totaled $3.87 billion, while enrollees (or their supplemental insurance) spent the remaining $500 million. In total, 6.8% of the elderly Medicare population received treatment for PAD. Treatment increased with age at rates of 4.5%, 7.5%, and 11.8% for individuals aged 65-74, 75-84, and >85 years, respectively. PAD-related costs accounted for approximately 13% of all Medicare Part A and B expenditures for the PAD-treated cohort, and 2.3% of total Medicare Part A and B expenditures. In conclusion, US national PAD-related costs are high, associated with inpatient care, and increase with age. PAD is treated at rates lower than the known PAD prevalence as only approximately one-third of the population with known PAD had detectable PAD-related health care costs in our analysis. The potential impact of earlier PAD detection and use of outpatient preventive strategies on total national PAD health care costs is unknown. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
12. Treatment of peripheral arterial disease--extending "intervention" to "therapeutic choice".
- Author
-
Hirsch AT and Hirsch, Alan T
- Published
- 2006
13. ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): Executive Summary A Collaborative Report From the American Association for Vascular Surgery/Society for Vascular Surgery, ⁎ [⁎] AAVS/SVS when Guideline initiated, now merged into SVS Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation
- Author
-
Hirsch, Alan T., Haskal, Ziv J., Hertzer, Norman R., Bakal, Curtis W., Creager, Mark A., Halperin, Jonathan L., Hiratzka, Loren F., Murphy, William R.C., Olin, Jeffrey W., Puschett, Jules B., Rosenfield, Kenneth A., Sacks, David, Stanley, James C., Taylor, Lloyd M., White, Christopher J., White, John, White, Rodney A., Antman, Elliott M., Smith, Sidney C., and Adams, Cynthia D.
- Published
- 2006
- Full Text
- View/download PDF
14. Mandate for Creation of a National Peripheral Arterial Disease Public Awareness Program: An Opportunity to Improve Cardiovascular Health.
- Author
-
Hirsch, Alan T., Gloviczki, Peter, Drooz, Alain, Lovell, Marge, and Creager, Mark A.
- Subjects
- *
ARTERIAL diseases , *CARDIOVASCULAR diseases , *PUBLIC health , *HEALTH surveys , *HEALTH promotion - Abstract
Background: There has been increasing recognition of the detrimental effect of peripheral arterial disease (PAD) on the health of Americans, and yet there is no common national program of public PAD education designed to diminish this effect. Format.' To heighten awareness of this problem, a 2-day PAD Public Education Strategy Meeting was recently attended by representatives of 17 professional societies and public health associations whose missions support the prevention, diagnosis, treatment, and rehabilitation of vascular diseases. This Public Education Strategy Meeting was intended to provide the rationale and structure to create a national PAD public awareness campaign to diminish the health effect of PAD and to improve cardiovascular outcomes in the United States. This document (1) provides the rationale for creation of a national PAD public education program; (2) reviews the development and success of national hypertension, hypercholesterolemia, and Women's Heart Health public education programs as models of educational efficacy; (3) elucidates how the work of many vascular professionals has led to a national consensus for creation of a national PAD public educational program; (4) provides an overview of the National Heart, Lung, and Blood Institute PAD education meeting; and (5) outlines the "next steps" required to accomplish these goals. Outcome: This meeting achieved consensus that we share responsibility for developing accurate, unified messages to promote PAD awareness and improved care. Participants agreed that the creation of such messages should be linked to plans to disseminate them to all Americans at risk. A consensus was reached that such messages, when commonly created and offered to the public, are most likely to achieve the rewards in better health that all Americans deserve. The Vascular Disease Foundation, a not-for-profit foundation whose mission includes public education about the prevention, diagnosis, treatment, and rehabilitation of PAD, will devote its resources to guide a new coalition in this process and to create a national PAD awareness campaign. During 2003 and 2004, the coalition will create the organizational underpinnings and time line for what will undoubtedly be a multiyear effort. Conclusion: Participants of the Public Education Strategy Meeting agreed to create a broad coalition to develop a National PAD Public Awareness Program, with the objectives to develop and disseminate public education messages on PAD. A successful national PAD education program will contribute to creation of a broader mandate to improve global cardiovascular health in the United States. [ABSTRACT FROM AUTHOR]
- Published
- 2004
15. Mandate for Creation of a National Peripheral Arterial Disease Public Awareness Program: An Opportunity to Improve Cardiovascular Health.
- Author
-
Hirsch, Alan T., Gloviczki, Peter, Drooz, Alain, Lovell, Marge, and Creager, Mark A.
- Subjects
- *
ARTERIAL diseases , *HEALTH , *HYPERTENSION , *HYPERCHOLESTEREMIA , *WOMEN'S health , *HEALTH education - Abstract
Discusses the rationale and structure to create a National Peripheral Arterial Disease (PAD) Public Awareness program in the U.S. Decrease in the health effect of PAD; Improvement in cardiovascular outcomes; Review of the development and success of national hypertension, hypercholesterolemia and Women's Heart Health public education programs as models of educational efficacy; Overview of the National Heart, Lung and Blood Institute PAD education meeting.
- Published
- 2004
- Full Text
- View/download PDF
16. The mandate for creation of a national peripheral arterial disease public awareness program: an opportunity to improve cardiovascular health.
- Author
-
Hirsch, Alan T., Gloviczki, Peter, Drooz, Alain, Lovell, Marge, and Creag, Mark A.
- Subjects
- *
ARTERIAL occlusions , *HYPERTENSION , *ARTERIAL diseases , *PUBLIC health ,TREATMENT of vascular diseases - Abstract
There has been increasing recognition of the detrimental impact of peripheral arterial disease (PAD) on the health of Americans, and yet there is no common national program of public PAD education designed to diminish this impact. To heighten awareness of this problem, a 2-day PAD Public Education Strategy Meeting was recently attended by representatives of 17 professional societies and public health associations whose missions support the prevention, diagnosis, treatment, and rehabilitation of vascular diseases. This Public Education Strategy Meeting was intended to provide the rationale and structure to create a national PAD public awareness campaign to diminish the health impact of PAD, and to improve cardiovascular outcomes in the USA. This paper: (1) provides the rationale for creation of a national PAD public education program; (2) reviews the development and success of national hypertension, hypercholesterolemia, and Women's Heart Health public education programs as models of educational efficacy; (3) elucidates how the work of many vascular professionals has led to a national consensus for creation of a national PAD public educational program; (4) provides an overview of the National Heart, Lung and Blood Institute PAD education meeting; and (5) outlines the 'next steps' required to accomplish these goals. This meeting achieved consensus that we share responsibility for developing accurate, unified messages to promote PAD awareness and improved care. Participants agreed that the creation of such messages should be linked to plans to disseminate them to all Americans at risk. A consensus was reached that such messages, when commonly created and offered to the public, are most likely to achieve the rewards in better health that all Americans deserve. The Vascular Disease Foundation, a not-for-profit foundation whose mission includes public education regarding the prevention, diagnosis, treatment, and rehabilitation of PAD, will devote its resources to guide a new coalition in this process and to create a national PAD awareness campaign. During 2003 and 2004, the coalition will create the organizational underpinnings and timeline for what will undoubtedly be a multi-year effort. In conclusion, participants of the Public Education Strategy Meeting agreed to create a broad coalition to develop a national PAD public awareness program, with the objectives to develop and disseminate public education messages on PAD. A successful national PAD education program will contribute to the creation of a broader mandate to improve global cardiovascular health in the USA. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
17. Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy.
- Author
-
Hiatt, William R., Hirsch, Alan T., Cooke, John P., Olin, Jeffrey W., Brater, D. Craig, and Creager, Mark A.
- Subjects
- *
INTERMITTENT claudication treatment , *SEROTONIN antagonists , *ARTERIAL occlusions , *MYOCARDIAL infarction , *GASTROINTESTINAL system , *QUALITY of life - Abstract
AT-1015 is a novel selective 5-HT2A serotonin receptor antagonist that is known to impair platelet aggregation and vasoconstriction. Serotonin has been hypothesized to contribute to claudication symptoms in individuals with peripheral arterial disease (PAD) via microvascular vasoconstrictor and thrombotic effects. AT-1015 was thus evaluated in 439 patients with claudication who were randomized in a double-blind, placebo-controlled trial comparing 10mg, 20mg, and 40mg BID versus placebo for 24 weeks. Treadmill walking performance was assessed by peak walking time (PWT) and pain-free walking time (PFWT). Quality of life (QoL) was measured by the Walking Impairment Questionnaire (WIQ) and the Health Status Survey SF-36. Limb hemodynamics was assessed with the ankle-brachial index (ABI). The 40mg arm was terminated prematurely by recommendation of the Data Safety Monitoring Committee due to an excess number of non-fatal myocardial infarctions. At study conclusion, there were no statistically significant differences in the mean change of PWT, PFWT, ABI and QoL between the 10mg and 20mg BID treatment groups compared with placebo. The proportion of patients who experienced an adverse event (AE) was similar across all treatment groups. Antimuscarinic and gastrointestinal AEs were more common in the AT-1015 treatment groups. Two deaths occurred: one in the placebo group and the other in the AT-1015 20mg group. Although a prolongation of the QTc interval was observed in all groups, this was not clinically significant (QTc > 500ms). Mean supine pulse rates were significantly increased in all AT-1015 treatment groups, consistent with predicted antimuscarinic effects. Population pharmacokinetic analysis fit a one-compartment model with first-order absorption and elimination. These data indicate that selective serotonin receptor blockade does not improve exercise tolerance or quality of life in individuals with claudication. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
18. The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease.
- Author
-
Hirsch, Alan T. and Duprez, Daniel
- Subjects
- *
VASCULAR diseases , *ANGIOTENSINS , *ATHEROSCLEROSIS , *ARTERIAL stenosis , *VASCULAR endothelium , *HYPERTENSION , *MORTALITY - Abstract
Peripheral arterial disease (PAD) is associated with significant morbidity and mortality, and yet remains under-recognized and under-treated. Atherosclerosis is the most common cause of lower extremity PAD and pharmacological interventions that alter this central patho- genic role of atherosclerosis may alter the natural history of PAD. There is growing evidence that the renin-angiotensin system (RAS) is a signi cant mediator of this disease process and that treatment with angiotensin-converting enzyme (ACE) inhibitors is associated with vasculopro- tective effects that are independent of the antihypertensive properties of these agents. Numerous lines of evidence suggest that ACE inhibitors directly inhibit the atherosclerotic process and improve vascular endothelial function. In patients with PAD, ACE inhibitors have been shown to improve peripheral circulation as measured by peripheral arterial blood pressure and by increases in peripheral blood flow. Preliminary evidence suggests that ACE inhibitors might improve clinical symptoms in patients with PAD. Recent evidence has confirmed that ACE inhibition is associated with a decrease in morbidity and mortality in patients with arterial disease without left ventricular dysfunction; this benefit was at least as great for the subset of patients with PAD. Overall, these data support a significant role for the RAS in the pathogenesis of all atherosclerotic diseases (including PAD) and suggest that the benefit is independent of the blood pressure lowering properties of these agents. These studies suggest that ACE inhibitor therapy should be considered in the routine management of individuals with PAD, regardless of whether they have hypertension or left ventricular dysfunction. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
19. Postgraduate training in vascular medicine: proposed requirements and standards.
- Author
-
Creager, Mark A., Hirsch, Alan T., Cooke, John P., Olin, Jeffrey W., Jaff, Michael R., Rooke, Thom, and Halperin, Jonathan L
- Subjects
- *
MEDICINE , *BLOOD vessels , *CARDIOLOGISTS , *HIGHER education - Abstract
Focuses on the requirements and standards of postgraduate training in vascular medicine. Guidelines of medicine training for cardiologists; Outlines of specific training methods in vascular medicine; Topics to be covered in vascular medicine.
- Published
- 2003
- Full Text
- View/download PDF
20. Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction.
- Author
-
Hirsch, Alan T and Gotto Jr, Antonio M
- Subjects
- *
ATHEROSCLEROSIS , *CORONARY disease - Abstract
Atherosclerosis is a form of arterial disease that manifests in the coronary circulation as coronary artery disease (CAD), in the carotid arteries as cerebrovascular disease, and in the aorta and lower extremity arteries as peripheral arterial disease (PAD). The systemic nature of the disease is reflected in the fact that individuals with PAD or carotid artery disease are more likely to have CAD than those without. Since individuals with PAD are at markedly increased risk of cardiovascular ischemic events, early identification of this population and more aggressive medical interventions could substantially improve both morbidity and survival. The incidence of PAD in the general population is high, and currently affects 8–10 million Americans. The risk of developing PAD is predicted by both age and common atherosclerosis risk factors (e.g., smoking and diabetes). Efficient office-based PAD detection depends on the application of objective techniques to establish this diagnosis. Objective noninvasive tests, such as measurement of the ankle–brachial index (ABI), are known to be more sensitive than traditional clinical assessments. Since the major threat to patients with PAD is from secondary cardiovascular ischemic events, a primary therapeutic goal is to modify atherosclerotic risk factors. While national recommendations mandate aggressive lowering of serum low-density lipoprotein cholesterol (LDL-C) levels as a primary treatment goal in all patients with overt atherosclerosis, as 'coronary heart disease risk equivalent' syndromes, individuals with PAD are less intensively treated than those with CAD. Statins are the most effective of current treatments in lowering LDL-C, and have proven efficacy in secondary prevention among patients with established CAD. The use of statin medications in high-risk groups such as PAD patients could prove particularly beneficial in reducing cardiovascular morbidity and mortality and therefore merits prospective clinical investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
21. Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care.
- Author
-
Hirsch, Alan T., Criqui, Michael H,, Treat-Jacobson, Diane, Regensteiner, Judith G., Creager, Mark A., Olin, Jeffrey W., Krook, Susan H., Hunninghake, Donald B., Comerota, Anthony J., Walsh, M. Eileen, McDermott, Mary M., and Hiatt, William R.
- Subjects
- *
ATHEROSCLEROSIS , *ARTERIAL diseases , *PRIMARY care , *ARTERIAL occlusions - Abstract
Presents a study to assess the feasibility of detecting peripheral arterial disease (PAD) in primary care clinics, patient and physician awareness of PAD, and intensity of risk factor treatment and use of antiplatelet therapies in primary care clinics. Design and setting; Patients; Main outcome measures; Results; Conclusions.
- Published
- 2001
- Full Text
- View/download PDF
22. PAD awareness, risk, and treatment: new resources for survival - the USA PARTNERS program.
- Author
-
Hirsch, Alan T and Hiatt, William R
- Abstract
Peripheral arterial disease (PAD) is a very common manifestation of atherosclerosis and is associated with a high risk of cardiovascular morbidity and mortality. Despite the magnitude of the problem, PAD is often under-recognized in clinical practice until its limb manifestations are severe or heart attack or stroke supervene. The PAD Awareness, Risk and Treatment: New Resources for Survival (PARTNERS) program, recently completed in the USA, had five aims: (1) creation of a method for detection of PAD in primary care practice; (2) assessment of the awareness of the PAD diagnosis in both patients and physicians; (3) assessment of the magnitude of the atherosclerotic risk factor burden and intensity of treatment of atherosclerotic risk factors in PAD patients; (4) assessment of the disease-specific and general quality of life of PAD patients in their communities; and (5) provision of an educational intervention to foster improved community-prescribed medical interventions for patients with PAD.Lack of public and physician interest in PAD contrasts with the high prevalence and poor medical prognosis of PAD. The intention of PARTNERS was to create a community-based program to measure current rates of PAD awareness, physician recognition and treatment intensity. Data obtained will form the basis of future clinical investigations to improve clinical care for PAD patients in the USA. [ABSTRACT FROM PUBLISHER]
- Published
- 2001
- Full Text
- View/download PDF
23. Active renin and angiotensinogen in cardiac interstitial fluid after myocardial infarction.
- Author
-
Hirsch, Alan T. and Opsahl, John A.
- Subjects
- *
ANGIOTENSINS , *MYOCARDIAL infarction , *RENIN , *PHYSIOLOGY - Abstract
Measures renin and angiotensinogen in plasma and myocardium 10 days after myocardial infarction. Increase in plasma and myocardial renin after infarction; Maintenance of myocardial angiotensinogen after infarction despite decreased plasma angiotensinogen and increased levels of myocardial renin; Renin-angiotensin system; Renin glycoforms.
- Published
- 1999
24. Active renin and angiotensinogen in cardiac interstitial fluid after myocardial infarction.
- Author
-
Hirsch, Alan T. and Opsahl, John A.
- Subjects
- *
RENIN , *ANGIOTENSINS , *MYOCARDIAL infarction - Abstract
Presents information on a study that aimed to characterize the relationship between plasma and cardiac active renin and angiotensinogen concentrations after myocardial infarction induced by coronary artery ligation in the rat. Methodology; Results; Discussion.
- Published
- 1999
- Full Text
- View/download PDF
25. The effect of caffeine on exercise tolerance and left ventricular function in patients with coronary artery disease.
- Author
-
Hirsch, Alan T., Gervino, Ernest V., Nakao, Shoichiro, Come, Patricia C., Silverman, Kenneth J., Grossman, William, Hirsch, A T, Gervino, E V, Nakao, S, Come, P C, Silverman, K J, and Grossman, W
- Subjects
- *
CAFFEINE , *CORONARY disease , *TREADMILL exercise tests , *ANGINA pectoris , *PATIENTS - Abstract
Study Objective: To determine whether acute oral caffeine ingestion by patients with coronary artery disease results in decreased treadmill exercise performance or deterioration of echocardiographic measures of systolic or diastolic left ventricular function.Design: Randomized, double-blind, placebo-controlled trial.Setting: Referral-based cardiovascular exercise laboratory at an urban teaching hospital.Patients: Thirteen volunteers with clinically stable coronary artery disease who had exercise tests after a 2-week caffeine-free washout period. Patients continued treatment with standard antianginal medications during the study period.Interventions: Maximal exercise treadmill testing and exercise echocardiography were done at baseline, after acute ingestion of a placebo beverage (97% caffeine-free coffee), or after drinking an identical beverage containing 250 mg of caffeine sodium benzoate.Measurements and Main Results: Acute ingestion of caffeine produced a serum level of 4.50 +/- 0.16 micrograms/mL, but had no effect on resting supine heart rate, blood pressure, left ventricular fractional shortening, posterior left ventricular wall thinning or peak rates of increase in left ventricular diastolic dimension. Despite a small increase in peak systolic blood pressure during exercise (baseline, 153 +/- 8; placebo, 154 +/- 8; caffeine, 161 +/- 7 mm Hg; P less than 0.05), exercise duration, time to onset of angina, and time to 0.1 mV ST depression did not differ after ingestion of placebo or caffeine. Rate-pressure product at onset of angina and onset of 0.1 mV of ST depression were also unchanged. In response to exercise, echocardiographic measures of left ventricular systolic and diastolic function were unchanged after caffeine compared with placebo ingestion.Conclusions: These data suggest that patients with exercise-induced ischemia who are receiving appropriate antianginal therapy tolerate the caffeine-equivalent of three cups of coffee without detrimental effect on intensity of ischemia, myocardial function, or exercise duration. [ABSTRACT FROM AUTHOR]- Published
- 1989
- Full Text
- View/download PDF
26. The global pandemic of peripheral artery disease.
- Author
-
Hirsch, Alan T. and Duval, Sue
- Subjects
- *
PERIPHERAL vascular diseases , *VASCULAR diseases , *PANDEMICS , *HIV infections , *PUBLIC health - Abstract
The authors discuss the global public health issue of peripheral artery disease. They reference the article "Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis" by Gerald Fowkes and colleagues, published within the issue. Peripheral artery disease is said to be more prevalent, with a higher case fatality rate, compared to HIV.
- Published
- 2013
- Full Text
- View/download PDF
27. Vascular disease, hypertension, and prevention: “from endothelium to clinical events”
- Author
-
Hirsch, Alan T.
- Published
- 2003
- Full Text
- View/download PDF
28. Infrarenal Aortic Occlusion.
- Author
-
Hirsch, Alan T. and Miedema, Michael D.
- Subjects
- *
ABDOMINAL aorta , *ARTERIAL occlusions , *ARTERIAL diseases , *ARTERIOSCLEROSIS , *LEG abnormalities , *STATINS (Cardiovascular agents) , *DISEASES - Abstract
The article focuses on the case of a 55 year old female smoker with hyperlipidemia who awoke with an acute onset of bilateral leg numbness and weakness. A discussion of diagnostic testing, including computed tomographic angiography, which was performed on the woman and revealed complete occlusion of the infrarenal abdominal aorta, is presented. A successful treatment strategy that was implemented with the woman, and which included antiplatelet therapy, statin therapy and smoking cessation intervention, is discussed.
- Published
- 2008
- Full Text
- View/download PDF
29. Balloon Angioplasty or Nitinol Stents for Peripheral-Artery Disease.
- Author
-
Hirsch, Alan T.
- Subjects
- *
LETTERS to the editor , *THERAPEUTICS - Abstract
A response by Alan T. Hirsch to letters to the editor about his editorial on therapeutic choices for patients with peripheral-artery disease in the May 4, 2006 issue of the "New England Journal of Medicine" is presented.
- Published
- 2006
- Full Text
- View/download PDF
30. Treatment of Peripheral Arterial Disease — Extending “Intervention†to “Therapeutic Choiceâ€.
- Author
-
Hirsch, Alan T.
- Subjects
- *
TRANSLUMINAL angioplasty , *VASCULAR diseases , *CORONARY restenosis - Abstract
The article presents the author's comments on a report about the important therapeutic advance in endovascular therapy for peripheral arterial disease published in the May 4, 2006 issue of the "New England Journal of Medicine." The author says that investigators randomly assigned 104 patients for primary treatment with either implantation of a balloon angioplasty or nitinol stent. The rates of restenosis were lower at 6 and 12 months in the stent group than in the angioplasty group.
- Published
- 2006
- Full Text
- View/download PDF
31. ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery, ⁎ Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease)
- Author
-
Hirsch, Alan T., Haskal, Ziv J., Hertzer, Norman R., Bakal, Curtis W., Creager, Mark A., Halperin, Jonathan L., Hiratzka, Loren F., Murphy, William R.C., Olin, Jeffrey W., Puschett, Jules B., Rosenfield, Kenneth A., Sacks, David, Stanley, James C., Taylor, Lloyd M., White, Christopher J., White, John, White, Rodney A., Antman, Elliott M., Smith, Sidney C., and Adams, Cynthia D.
- Published
- 2006
- Full Text
- View/download PDF
32. News from the Society for Vascular Medicine and Biology.
- Author
-
Hirsch, Alan T
- Subjects
- *
MEDICAL societies , *MEETINGS , *CITATION indexes , *MEDICAL personnel-caregiver relationships - Abstract
Provides updates on the Society for Vascular Medicine and Biology in the United States. Growth of vascular medicine; Success of the ninth annual meeting of the society; Achievement of citation status by the 'Vascular Medicine' journal; Collaboration between primary care and vascular specialty professionals.
- Published
- 1998
- Full Text
- View/download PDF
33. The Society for Vascular Medicine: The first quarter century.
- Author
-
Creager, Mark A, Hiatt, William R, Hirsch, Alan T, Olin, Jeffrey W, Jaff, Michael R, Cooke, John P, Rooke, Thom, Beckman, Joshua A, and Froehlich, James B
- Subjects
- *
MEDICAL societies , *VASCULAR medicine , *PROFESSIONAL associations , *HEALTH education , *VASCULAR diseases , *CLINICAL trials - Abstract
The Society for Vascular Medicine was founded in 1989. During the subsequent 25 years, the Society has grown to approximately 500 members and has achieved international recognition while making important contributions to vascular disease education, clinical vascular medicine and biology research, and patient care. In celebration of the Society’s 25th anniversary, its past and current presidents reflect on the Society’s history, challenges, and achievements, and emphasize the vital role of the SVM in the discipline of vascular medicine. [ABSTRACT FROM PUBLISHER]
- Published
- 2015
- Full Text
- View/download PDF
34. Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease.
- Author
-
Bauer, Timothy A, Wolff, Andrew A, Hirsch, Alan T, Meng, Lisa L, Rogers, Kevin, Malik, Fady I, and Hiatt, William R
- Subjects
- *
ARTERIAL diseases , *TROPONIN , *VASCULAR diseases , *SKELETAL muscle , *ISCHEMIA - Abstract
Tirasemtiv (CK-2017357), a novel small-molecule activator of the fast skeletal muscle troponin complex, slows the rate of calcium release from troponin, thus sensitizing fast skeletal muscle fibers to calcium. In preclinical studies, tirasemtiv increased muscle force and delayed the onset and reduced the extent of muscle fatigue during hypoxia in vitro and muscle ischemia in situ. This study evaluated the effect of single doses of tirasemtiv on measures of skeletal muscle function and fatigability in patients with stable calf claudication due to peripheral artery disease (PAD). Sixty-one patients with an ankle–brachial index ≤0.90 in the leg with claudication received single double-blind doses of tirasemtiv 375 mg and 750 mg and matching placebo in random order about 1 week apart. After 33 patients were treated, the 750 mg dose was decreased to 500 mg due to adverse events and these dose groups were combined for analysis. On each study day, bilateral heel-raise testing was performed before and at 3 and 6 hours after dosing; a 6-minute walk test was performed at 4 hours after dosing. Claudicating calf muscle performance was increased at the highest dose and plasma concentration of tirasemtiv; however, the 6-minute walk distance decreased with both the dose and plasma concentration of tirasemtiv, possibly due to dose-related adverse events, particularly dizziness, that could impede walking ability. In conclusion, the mechanism of fast skeletal muscle troponin activation improved muscle function but not 6-minute walking distance in patients with claudication due to PAD. ClinicalTrials.gov Identifier: NCT01131013 [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
35. Carotid plaque and intima-media thickness and the incidence of ischemic events in patients with atherosclerotic vascular disease.
- Author
-
Keo, Hong H, Baumgartner, Iris, Hirsch, Alan T, Duval, Sue, Steg, Ph Gabriel, Pasquet, Blandine, Bhatt, Deepak L, and Roether, Joachim
- Subjects
- *
ATHEROSCLEROSIS , *CORONARY disease , *VASCULAR diseases , *HOSPITAL care , *MORTALITY , *MYOCARDIAL infarction , *PATIENTS ,CAROTID artery abnormalities - Abstract
We aimed to evaluate whether carotid intima-media thickness (CIMT) or the presence of plaque can confer additional predictive value of future cardiovascular (CV) ischemic events in patients with pre-existing atherosclerotic vascular disease. We identified 2317 patients enrolled in the REduction of Atherothrombosis for Continued Health (REACH) registry who had atherosclerotic vascular disease and baseline CIMT measurements. The entire range of CIMT was divided into quartiles and the fourth quartile (≥ 1.5 mm) was defined as carotid plaque. Mean ± standard deviation baseline CIMT was 1.31 ± 0.65 mm. Associated CV ischemic events and vascular-related hospitalizations were evaluated over a 2-year follow-up. There was a positive increase in adjusted hazard ratios (HRs) for all-cause mortality (p = 0.04 for trend) and the quadruple endpoint (CV death, myocardial infarction (MI), stroke, hospitalization for CV events) with increasing quartiles of CIMT (p = 0.0008 for trend), which was mainly driven by the fourth quartile (carotid plaque). HRs for all-cause mortality, CV death, CV death/MI/stroke and the quadruple endpoint comparing the highest (carotid plaque) with the lowest CIMT quartile were 2.09 (95% CI, 1.07–4.10; p = 0.03); 2.49 (1.10–5.67; p = 0.03); 1.71 (1.10–2.67; p = 0.02); and 1.73 (1.31–2.27; p = 0.0001). In conclusion, our analyses suggest that the presence of carotid plaque, rather than the thickness of intima-media, appears to be associated with increased risk of CV morbidity and mortality, but confirmation of these findings in other population and prospective studies is required. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
36. A High Ankle-Brachial Index Is Associated With Increased Cardiovascular Disease Morbidity and Lower Quality of Life
- Author
-
Allison, Matthew A., Hiatt, William R., Hirsch, Alan T., Coll, Joseph R., and Criqui, Michael H.
- Subjects
- *
HEART failure , *CARDIAC arrest , *MEDICAL care , *HEART diseases - Abstract
Objectives: The purpose of this study is to determine if an ankle-brachial index (ABI) ≥1.40 is associated with reduced quality of life (QoL). Background: Ankle-brachial index values ≥1.40 have been associated with some cardiovascular disease (CVD) risk factors and increased mortality, but the relationship to other disease morbidity such as reduced QoL has not been previously evaluated. Methods: The PARTNERS (PAD Awareness, Risk and Treatment: New Resources for Survival) program was a national cross-sectional study of 7,155 patients age >50 years recruited from 350 primary care sites. All sites performed the ABI using a Doppler device and a standardized technique. Results: A total of 296 subjects had an ABI ≥1.40 in at least 1 leg, and 4,420 had an ABI between 0.90 and 1.40. Diabetes, male gender, and waist circumference were positively associated with a high ABI, and smoking and dyslipidemia were inversely associated with a high ABI. After adjustment for age, gender, and the traditional CVD risk factors, and accounting for multiple comparisons, the high ABI group had significantly higher odds for foot ulcers (p < 0.005) and borderline associations with heart failure, stroke, and neuropathy. After the same adjustments and adjusting for patients with other CVD, the high ABI group scored 2.0 points lower on the physical component scale on the Medical Outcomes Study Standard Form–36 and 5.5 points lower on the Walking Impairment Questionnaire walking distance domain (p < 0.05 for both). Conclusion: Individuals with a high ABI have higher odds for foot ulcers and neuropathy, as well as lower scores on some physical functioning QoL domains. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
37. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus
- Author
-
Bhatt, Deepak L., Marso, Steven P., Hirsch, Alan T., Ringleb, Peter A., Hacke, Werner, and Topol, Eric J.
- Published
- 2002
- Full Text
- View/download PDF
38. ACC/AHA/SCAI/SIR/SVM 2018 Appropriate Use Criteria for Peripheral Artery Intervention: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and Society for Vascular Medicine
- Author
-
Bailey, Steven R., Beckman, Joshua A., Dao, Timothy D., Misra, Sanjay, Sobieszczyk, Piotr S., White, Christopher J., Wann, L. Samuel, Dao, Timothy, Aronow, Herbert D., Fazel, Reza, Gornik, Heather L., Gray, Bruce H., Halperin, Jonathan L., Hirsch, Alan T., Jaff, Michael R., Krishnamurthy, Venkataramu, Parikh, Sahil A., Reed, Amy B., Shamoun, Fadi, and Shugart, Rita E.
- Subjects
- *
INTERMITTENT claudication , *VASCULAR medicine , *INTERVENTIONAL radiology , *CARDIOLOGISTS , *TIBIAL arteries , *TASK forces , *INTRA-aortic balloon counterpulsation - Published
- 2019
- Full Text
- View/download PDF
39. Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study.
- Author
-
Ding, Ning, Kwak, Lucia, Ballew, Shoshana H., Jaar, Bernard, Hoogeveen, Ron C., Ballantyne, Christie M., Sharrett, A. Richey, Folsom, Aaron R., Heiss, Gerardo, Salameh, Maya, Coresh, Josef, Hirsch, Alan T., Selvin, Elizabeth, and Matsushita, Kunihiro
- Subjects
- *
ATHEROSCLEROSIS , *PERIPHERAL vascular diseases , *HEMOGLOBINS , *GLYCEMIC index , *GLUCOKINASE - Abstract
Background and aims Traditional glycemic markers, fasting glucose and hemoglobin A1c (HbA1c), predict incident peripheral artery disease (PAD). However, it is unknown whether nontraditional glycemic markers, fructosamine, glycated albumin, and 1,5-anhydroglucitol, are associated with PAD and whether these glycemic markers demonstrate particularly strong associations with severe PAD, critical limb ischemia (CLI). Methods We quantified the associations of these five glycemic markers with incident PAD (hospitalizations with PAD diagnosis or leg revascularization) in 11,634 ARIC participants using Cox regression models. Participants were categorized according to diabetes diagnosis and clinical cut-points of glycemic markers (nontraditional glycemic markers were categorized according to percentiles corresponding to the HbA1c cut-points). Results Over a median follow-up of 20.7 years, there were 392 cases of PAD (133 were CLI with tissue loss). HbA1c was more strongly associated with incident PAD than fasting glucose, with adjusted hazard ratios (HR) 6.00 (95% CI, 3.73–9.66) for diagnosed diabetes with HbA1c ≥ 7% and 3.53 (2.39–5.22) for no diagnosed diabetes with HbA1c ≥ 6.5% compared to no diagnosed diabetes with HbA1c <5.7%. Three nontraditional glycemic markers demonstrated risk gradients intermediate between HbA1c and fasting glucose and their risk gradients were substantially attenuated after adjusting for HbA1c. All glycemic markers consistently demonstrated stronger associations with CLI than PAD without CLI ( p for difference <0.02 for all glycemic markers). Conclusions Nontraditional glycemic markers were associated with incident PAD independent of fasting glucose but not necessarily HbA1c. Our results also support the importance of glucose metabolism in the progression to CLI. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
40. Ankle-brachial index and physical function in older individuals: The Atherosclerosis Risk in Communities (ARIC) study.
- Author
-
Matsushita, Kunihiro, Ballew, Shoshana H., Sang, Yingying, Kalbaugh, Corey, Loehr, Laura R., Hirsch, Alan T., Tanaka, Hirofumi, Heiss, Gerardo, Windham, B. Gwen, Selvin, Elizabeth, and Coresh, Josef
- Subjects
- *
ATHEROSCLEROSIS risk factors , *ANKLE brachial index , *OLDER people physiology , *COMMUNITIES , *PHYSICAL activity - Abstract
Background and aims Most prior studies investigating the association of lower extremity peripheral artery disease (PAD) with physical function were small or analyzed selected populations (e.g., patients at vascular clinics or persons with reduced function), leaving particular uncertainty regarding the association in the general community. Methods Among 5262 ARIC participants (age 71–90 years during 2011–2013), we assessed the cross-sectional association of ankle-brachial index (ABI) with the Short Physical Performance Battery (SPPB) score (0–12), its individual components (chair stands, standing balance, and gait speed) (0–4 points each), and grip strength after accounting for potential confounders, including a history of coronary disease, stroke, or heart failure. Results There were 411 participants (7.8%) with low ABI ≤0.90 and 469 (8.9%) participants with borderline low ABI 0.91–1.00. Both ABI ≤0.90 and 0.91–1.00 were independently associated with poor physical function (SPPB score ≤6) compared to ABI 1.11–1.20 (adjusted odds ratio 2.10 [95% CI 1.55–2.84] and 1.86 [1.38–2.51], respectively). The patterns were largely consistent across subgroups by clinical conditions (e.g., leg pain or other cardiovascular diseases), in every SPPB component, and for grip strength. ABI >1.3 (472 participants [9.0%]), indicative of non-compressible pedal arteries, was related to lower physical function as well but did not necessarily reach significance. Conclusions In community-dwelling older adults, low and borderline low ABI suggestive of PAD were independently associated with poorer systemic physical function compared to those with normal ABI. Clinical attention to PAD as a potential contributor to poor physical function is warranted in community-dwelling older adults. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
41. Serum 25-hydroxyvitamin D is associated with incident peripheral artery disease among white and black adults in the ARIC study cohort.
- Author
-
Rapson, Ian R., Michos, Erin D., Alonso, Alvaro, Hirsch, Alan T., Matsushita, Kunihiro, Reis, Jared P., and Lutsey, Pamela L.
- Subjects
- *
ARTERIAL diseases , *ANKLE brachial index , *BODY mass index , *VITAMIN D , *WHITE people , *BLACK people , *DISEASES - Abstract
Background and aims Low 25-hydroxyvitamin D [25(OH)D] concentrations have been associated with peripheral artery disease (PAD). Prevalence of low 25(OH)D and PAD differ between whites and blacks. However, these associations have not been studied prospectively or in a population based cohort. We tested the hypothesis that low 25(OH)D is associated with greater risk of incident PAD in white and black adults. Methods 25(OH)D was measured in serum collected at ARIC visit 2 (1990–1992). We followed 11,789 ARIC participants free of PAD at visit 2 through 2011 for incident PAD events. 25(OH)D (ng/mL) was categorized as deficient (<20), insufficient (20 to <30) or sufficient (≥30). PAD was defined by an ankle brachial index (ABI) of <0.9 at ARIC visits 3 or 4 or a hospital diagnosis with an ICD-9 code indicating PAD during follow-up. Analysis used multivariable-adjusted Cox proportional hazards regressions. Results Over a mean follow-up of 17.1 years, 1250 incident PAD events were identified. 22% of whites and 61% of blacks were 25(OH)D deficient. After adjustment for demographic characteristics, the hazard ratio (95% CI) of PAD in participants with deficient versus sufficient 25(OH)D was 1.49 (1.26, 1.76). Inclusion of BMI, physical activity, and smoking status attenuated the association [1.25 (1.06, 1.48)]. The association between 25(OH)D and PAD was qualitatively stronger in blacks ( p for interaction = 0.20). Conclusions Deficient 25(OH)D was associated with increased risk of PAD in black and white participants. Whether treatment of low vitamin D through supplementation or modest sunlight exposure prevents PAD is unknown. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
42. The effect of gender on outcomes of aortoiliac artery interventions for claudication.
- Author
-
Krishnamurthy, Venkataramu N., Naeem, Muhammad, Murphy, Timothy P., Cerezo, Joselyn, Jordan, Paul Gaither, Goldberg, Suzanne H., Ershowd, Abby G., Hirsch, Alan T., Oldenburg, Niki, and Cutlip, Donald E.
- Subjects
- *
ILIAC artery , *INTERMITTENT claudication , *HEALTH outcome assessment , *REVASCULARIZATION (Surgery) , *COMPARATIVE studies , *BODY mass index - Abstract
Objective: To explore the relationship between gender, native artery diameters, and outcomes of stent revascularization (ST) in the "Claudication: Exercise versus Endoluminal Revascularization" trial. Methods: A comparative analysis was performed of the impact of gender, age, weight, height, body mass index, and body surface area on revascularization outcomes at baseline and 6 months in 55 arterial segments of aorta, common iliac artery, and external iliac artery (EIA). Results: Women demonstrated smaller diameter of the EIA. However, the clinical outcomes of revascularization were not negatively affected by the gender-based differences. Conclusion: Gender-based differences are unlikely to significantly impact outcome of ST. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
43. The Contribution of Tobacco Use to High Health Care Utilization and Medical Costs in Peripheral Artery Disease: A State-Based Cohort Analysis.
- Author
-
Duval, Sue, Long, Kirsten Hall, Roy, Samit S., Oldenburg, Niki C., Harr, Kelsey, Fee, Rebecca M., Sharma, Ratnendra R., Alesci, Nina L., and Hirsch, Alan T.
- Abstract
Background: Tobacco use is an important preventable cause of peripheral artery disease (PAD) and a major determinant of adverse clinical outcomes.Objectives: This study hypothesized that tobacco use by PAD patients would be associated with higher health care utilization and associated costs.Methods: We conducted a retrospective, cross-sectional study using 2011 claims data from the largest Minnesota health plan. The total cohort included individuals with 12 months of continuous enrollment and ≥ 1 PAD-related claim. Tobacco cessation pharmacotherapy billing codes were queried in a subgroup with pharmacy benefits. Outcomes were total costs, annual proportion of members hospitalized, and primary discharge diagnoses.Results: A PAD cohort of 22,203 was identified, comprising 1,995 (9.0%) tobacco users. A subgroup of 9,027 with pharmacy benefits included 1,158 (12.8%) tobacco users. The total cohort experienced 22,220 admissions. The pharmacy benefits subgroup experienced 8,152 admissions. Within 1 year, nearly one-half the PAD tobacco users were hospitalized, 35% higher than nonusers in the total cohort (p < 0.001) and 30% higher in the subgroup (p < 0.001). In both cohorts, users were more frequently admitted for peripheral or visceral atherosclerosis (p < 0.001), acute myocardial infarction (p < 0.001), and coronary heart disease (p < 0.05). Observed costs in the total cohort were $64,041 for tobacco users versus $45,918 for nonusers. Costs for tobacco users also were consistently higher for professional and facility-based care, persisting after adjustment for age, sex, comorbidities, and insurance type.Conclusions: Tobacco use in PAD is associated with substantial increases in PAD-related hospitalizations, coronary heart disease and PAD procedures, and significantly greater costs. The results suggest that immediate provision of tobacco cessation programs may be especially cost effective. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
44. Movement, Function, Pain, and Postoperative Edema in Axillary Web Syndrome.
- Author
-
Koehler, Linda A., Blaes, Anne H., Haddad, Tuffia C., Hunter, David W., Hirsch, Alan T., and Ludewig, Paula M.
- Subjects
- *
DIAGNOSIS of edema , *LYMPH node surgery , *ANALYSIS of variance , *BREAST tumors , *CONFIDENCE intervals , *RANGE of motion of joints , *LIFE skills , *LONGITUDINAL method , *MULTIVARIATE analysis , *PAIN , *PROBABILITY theory , *QUESTIONNAIRES , *RESEARCH funding , *SHOULDER joint , *SURGICAL complications , *LOGISTIC regression analysis , *SAMPLE size (Statistics) , *STATISTICAL power analysis , *EFFECT sizes (Statistics) , *PAIN measurement , *BODY movement , *VISUAL analog scale , *ABDUCTION (Kinesiology) , *DISEASE incidence , *REPEATED measures design , *DISEASE prevalence , *DATA analysis software , *DESCRIPTIVE statistics , *SENTINEL lymph node biopsy , *AXILLARY web syndrome , *ODDS ratio - Abstract
Background. Axillary web syndrome (AWS) is a condition that may develop following breast cancer surgery and that presents as a palpable axillary cord of tissue. Objective. The purposes of this study were: (1) to determine the clinical characteristics of AWS related to movement, function, pain, and postoperative edema and (2) to define the incidence of and risk factors for AWS within the first 3 months following breast cancer surgery. Design. This was a prospective cohort study with a repeated-measures design. Methods. Women who underwent breast cancer surgery with sentinel node biopsy or axillary lymph node dissection (N=36) were assessed for AWS, shoulder range of motion, function, pain, and postoperative edema (using girth measurements, bioimpedance, and tissue dielectric constant) at 2, 4, and 12 weeks. Demographic characteristics were used for risk analysis. Results. Seventeen women (47.2%) developed AWS, and AWS persisted in 10 participants (27.8%) at 12 weeks. Abduction range of motion was significantly lower in the AWS group compared with the non-AWS group at 2 and 4 weeks. There were no differences between groups in measurements of function, pain, or edema at any time point. Trunk edema measured by dielectric constant was present in both groups, with an incidence of 55%. Multivariate analysis determined lower body mass index as being significantly associated with AWS (odds ratio=0.86; 95% confidence intervals.74, 1.00). Limitations. Limitations included a short follow-up time and a small sample size. Conclusion. Axillary web syndrome is prevalent following breast/axilla surgery for early-stage breast cancer and may persist beyond 12 weeks. The early consequences include movement restriction, but the long-term effects of persistent AWS cords are yet unknown. Low body mass index is considered a risk factor for AWS. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
45. Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation.
- Author
-
Bekwelem, Wobo, Connolly, Stuart J., Halperin, Jonathan L., Adabag, Selcuk, Duval, Sue, Chrolavicius, Susan, Pogue, Janice, Ezekowitz, Michael D., Eikelboom, John W., Wallentin, Lars G., Yusuf, Salim, and Hirsch, Alan T.
- Subjects
- *
ATRIAL fibrillation , *THROMBOEMBOLISM , *CLINICAL trials , *COAGULATION , *PERFUSION , *DISEASE incidence - Abstract
Background-Nonvalvular atrial fibrillation is a major cause of thromboembolic events. In comparison with atrial fibrillation-related stroke, extracranial systemic embolic events (SEEs) remain poorly defined. Methods and Results-All suspected SEEs reported among 37 973 participants of 4 large contemporary randomized clinical trials of anticoagulation in atrial fibrillation were independently readjudicated for clinical and objective evidence of sudden loss of perfusion of a limb or organ. Over 91 746 patient-years of follow-up, 221 SEEs occurred in 219 subjects. The SEE incidence was 0.24 of 100 and stroke incidence was 1.92 of 100 patient-years. In comparison with patients with stroke, those with SEE were more often female (56% versus 47%; P=0.01) and had comparable mean age (73.1±8.5 versus 73.5±8.8 years; P=0.57) and mean CHADS2 scores (2.4±1.3 versus 2.5±1.2; P=0.33). SEEs more frequently involved the lower extremity (58%) than visceral-mesenteric (31%) or upper extremity (10%). SEE-related care involved clinic assessment alone in 5%, 30% were hospitalized without procedures, 60% underwent endovascular or surgical intervention, and 5% underwent amputation. Within 30 days, 54% of patients recovered fully, 20% survived with deficits, and 25% died. Thirty-day mortality was greater after visceral-mesenteric than lower- or upper-extremity SEE (55%, 17%, and 9%, respectively, P≤0.0001). The relative risk of death throughout follow-up was 4.33 (95% confidence interval, 3.29-5.70) after SEE versus 6.79 (95% confidence interval, 6.22-7.41) after stroke in comparison with patients without either event. Conclusions-SEE constituted 11.5% of clinically recognized thromboembolic events in patients with atrial fibrillation and was associated with high morbidity and mortality. SEE mortality was comparable to that of ischemic stroke and varied by anatomic site. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
46. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study.
- Author
-
Murphy, Timothy P, Cutlip, Donald E, Regensteiner, Judith G, Mohler 3rd, Emile R, Cohen, David J, Reynolds, Matthew R, Massaro, Joseph M, Lewis, Beth A, Cerezo, Joselyn, Oldenburg, Niki C, Thum, Claudia C, Jaff, Michael R, Comerota, Anthony J, Steffes, Michael W, Abrahamsen, Ingrid H, Goldberg, Suzanne, Hirsch, Alan T, and Mohler, Emile R 3rd
- Abstract
Background: Treatment for claudication that is due to aortoiliac peripheral artery disease (PAD) often relies on stent revascularization (ST). However, supervised exercise (SE) is known to provide comparable short-term (6-month) improvements in functional status and quality of life. Longer-term outcomes are not known.Objectives: The goal of this study was to report the longer-term (18-month) efficacy of SE compared with ST and optimal medical care (OMC).Methods: Of 111 patients with aortoiliac PAD randomly assigned to receive OMC, OMC plus SE, or OMC plus ST, 79 completed the 18-month clinical and treadmill follow-up assessment. SE consisted of 6 months of SE and an additional year of telephone-based exercise counseling. Primary clinical outcomes included objective treadmill-based walking performance and subjective quality of life.Results: Peak walking time improved from baseline to 18 months for both SE (5.0 ± 5.4 min) and ST (3.2 ± 4.7 min) significantly more than for OMC (0.2 ± 2.1 min; p < 0.001 and p = 0.04, respectively). The difference between SE and ST was not significant (p = 0.16). Improvement in claudication onset time was greater for SE compared with OMC, but not for ST compared with OMC. Many disease-specific quality-of-life scales demonstrated durable improvements that were greater for ST compared with SE or OMC.Conclusions: Both SE and ST had better 18-month outcomes than OMC. SE and ST provided comparable durable improvement in functional status and in quality of life up to 18 months. The durability of claudication exercise interventions merits its consideration as a primary PAD claudication treatment. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
47. Development of administrative data algorithms to identify patients with critical limb ischemia.
- Author
-
Bekwelem, Wobo, Bengtson, Lindsay GS, Oldenburg, Niki C, Winden, Tamara J, Keo, Hong H, Hirsch, Alan T, and Duval, Sue
- Subjects
- *
ISCHEMIA , *ALGORITHMS , *INPATIENT care , *OCCUPATIONAL therapist & patient ,INTERNATIONAL Statistical Classification of Diseases & Related Health Problems - Abstract
Administrative data have been used to identify patients with various diseases, yet no prior study has determined the utility of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)-based codes to identify CLI patients. CLI cases (n=126), adjudicated by a vascular specialist, were carefully defined and enrolled in a hospital registry. Controls were frequency matched to cases on age, sex and admission date in a 2:1 ratio. ICD-9-CM codes for all patients were extracted. Algorithms were developed using frequency distributions of these codes, risk factors and procedures prevalent in CLI. The sensitivity for each algorithm was calculated and applied within the hospital system to identify CLI patients not included in the registry. Sensitivity ranged from 0.29 to 0.92. An algorithm based on diagnosis and procedure codes exhibited the best overall performance (sensitivity of 0.92). Each algorithm had differing CLI identification characteristics based on patient location. Administrative data can be used to identify CLI patients within a health system. The algorithms, developed from these data, can serve as a tool to facilitate clinical care, research, quality improvement, and population surveillance. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
48. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
- Author
-
Anderson, Jeffrey L, Halperin, Jonathan L, Albert, Nancy, Bozkurt, Biykem, Brindis, Ralph G, Curtis, Lesley H, Demets, David, Guyton, Robert A, Hochman, Judith S, Kovacs, Richard J, Ohman, E Magnus, Pressler, Susan J, Sellke, Frank W, Shen, Win-Kuang, Rooke, Thom W, Hirsch, Alan T, Misra, Sanjay, Sidawy, Anton N, Beckman, Joshua A, and Findeiss, Laura
- Published
- 2013
- Full Text
- View/download PDF
49. An evidence-based score to detect prevalent peripheral artery disease (PAD).
- Author
-
Duval, Sue, Massaro, Joseph M, Jaff, Michael R, Boden, William E, Alberts, Mark J, Califf, Robert M, Eagle, Kim A, D’Agostino, Ralph B, Pedley, Alison, Fonarow, Gregg C, Murabito, Joanne M, Steg, P Gabriel, Bhatt, Deepak L, and Hirsch, Alan T
- Subjects
- *
EVIDENCE-based medicine , *ARTERIAL diseases , *MEDICAL screening , *LOGISTIC regression analysis , *HEART failure , *BODY mass index - Abstract
Detection of peripheral artery disease (PAD) typically entails collection of medical history, physical examination, and noninvasive imaging, but whether a risk factor-based model has clinical utility in population screening is unclear. Our objective was to derive and validate a new score for estimating PAD probability in individuals or populations. PAD presence was determined by a history of previous or current intermittent claudication associated with an ankle–brachial index (ABI) of < 0.9 or previous lower extremity arterial intervention. Multivariable stepwise logistic regression identified cross-sectional correlates of PAD from demographic, clinical, and laboratory variables. Analyses were derived from 18,049 US REACH (REduction of Atherothrombosis for Continued Health) Registry outpatients with a complete baseline risk factor profile (enrolled from December 2003 to June 2004). Model performance was assessed internally using 10-fold cross validation, and effect estimates were used to generate the score. The model was externally validated using the Framingham Offspring Study. Age, sex, smoking, diabetes mellitus, body mass index, hypertension stage, and history of heart failure, coronary artery disease, and cerebrovascular disease were predictive of PAD prevalence. The model had reasonable discrimination on derivation and internal validation (c-statistic = 0.61 and 0.60, respectively) and external validation (c-statistic = 0.63 [ABI < 0.9] or 0.64 [clinical PAD]). The model-estimated PAD prevalence varied more than threefold from lowest to highest decile (range, 4.5–16.7) and corresponded closely with actual PAD prevalence in each population. In conclusion, this new tool uses clinical variables to estimate PAD prevalence. While predictive power may be limited, it may improve PAD detection in vulnerable, at-risk populations. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
50. Future Directions for Cardiovascular Disease Comparative Effectiveness Research: Report of a Workshop Sponsored by the National Heart, Lung, and Blood Institute
- Author
-
Hlatky, Mark A., Douglas, Pamela S., Cook, Nakela L., Wells, Barbara, Benjamin, Emelia J., Dickersin, Kay, Goff, David C., Hirsch, Alan T., Hylek, Elaine M., Peterson, Eric D., Roger, Véronique L., Selby, Joseph V., Udelson, James E., and Lauer, Michael S.
- Subjects
- *
CARDIOVASCULAR diseases , *COMPARATIVE studies , *RANDOMIZED controlled trials , *CLINICAL trials , *MEDICAL research - Abstract
Comparative effectiveness research (CER) aims to provide decision makers with the evidence needed to evaluate the benefits and harms of alternative clinical management strategies. CER has become a national priority, with considerable new research funding allocated. Cardiovascular disease is a priority area for CER. This workshop report provides an overview of CER methods, with an emphasis on practical clinical trials and observational treatment comparisons. The report also details recommendations to the National Heart, Lung, and Blood Institute for a new framework for evidence development to foster cardiovascular CER, and specific studies to address 8 clinical issues identified by the Institute of Medicine as high priorities for cardiovascular CER. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.